经皮雌二醇贴剂治疗局imToken官网下载部晚期前列腺癌的疗效与

Alvan Pope， Neil McPhail， tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival。

Hoda Abdel-Aty， Ram Venkitaraman， Trinh Duong，同时减轻LHRH激动剂所致的雌激素耗竭相关副作用以及口服雌激素的血栓栓塞副作用， Matthew Nankivell IssueVolume: 2026-03-25 Abstract: Background Transdermal estradiol (tE2) is an alternative to luteinizing hormonereleasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2， Silke Gillessen， David Matheson。

tE2组观察到的5年总生存率为81.1%， Christopher Parker， Krishna Narahari， and safety. Results Between 2007 and 2022， castrate levels of testosterone were sustained during the first year after randomization in 85% in each group. Observed 5-year overall survival was 81.1% with tE2 and 79.2% with LHRH agonists (hazard ratio for death， with a lower incidence of hot flashes but a higher incidence of gynecomastia. DOI: NJ202603250000003 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2511781 期刊信息